BioSpace News Archive

Alzheimer disease is the most common form of dementia which can impair the person’s daily functioning and is mainly characterized by loss of memory, loss of cognitive function and functional impairment.

Many in vitro models simulate nonalcoholic steatohepatitis (NASH) conditions by culturing human hepatocytes in fatty acid-enriched media.

Rise in the incidence of actinic keratosis has given way to desirable use of up-to-date therapeutics, which in turn has led to a steep increase in the number of impending drugs in pipeline.

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastro intestine that includes ulcerative colitis and Crohn’s disease.

Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that the European Commission (EC) has expanded the current indication for AYVAKYT® (avapritinib) to include monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN) or mast cell leukemia (MCL), after at least one systemic therapy.

Muscle stimulators are making their way into the mainstream day by day and playing a crucial role in improve health conditions.

Osteoarthritis is one of the most draining diseases and so far, no therapy can effectively treat structural deterioration of bones and cartilage or any course of medicine to reverse any existing structural defects.

In the last few years, use of advanced medical devices over their conventional counterparts has highly increased, and surge in healthcare expenditure has played a pivotal role in the same.

The global acute repetitive seizures market is expected to grow at a CAGR of about 46.7% over the forecast period and to reach valuation US$ 4.3 billion by 2027.

The clinical communication and collaboration market is growing at a registered CAGR of 11.6% over the forecast period and to reach valuation US$ 3.6 billion by 2029.